
RPRX
Royalty Pharma PLC
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
36.710
Open
36.650
VWAP
36.51
Vol
1.93M
Mkt Cap
20.62B
Low
36.290
Amount
70.36M
EV/EBITDA(TTM)
15.53
Total Shares
452.11M
EV
29.52B
EV/OCF(TTM)
10.93
P/S(TTM)
9.55
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
705.46M
+31.37%
1.023
+6.39%
784.63M
+38.87%
0.999
-3.95%
770.48M
+29.71%
1.273
+10.56%
Estimates Revision
The market is revising Downward the revenue expectations for Royalty Pharma plc (RPRX) for FY2025, with the revenue forecasts being adjusted by -1.81% over the past three months. During the same period, the stock price has changed by 12.69%.
Revenue Estimates for FY2025
Revise Downward

-1.81%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-1.4%
In Past 3 Month
Stock Price
Go Up

+12.69%
In Past 3 Month
4 Analyst Rating

19.31% Upside
Wall Street analysts forecast RPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX is 43.75 USD with a low forecast of 40.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy

19.31% Upside
Current: 36.670

Low
40.00
Averages
43.75
High
51.00

19.31% Upside
Current: 36.670

Low
40.00
Averages
43.75
High
51.00
Citi
Buy
maintain
$40 -> $42
2025-07-22
Reason
Citi
Price Target
$40 -> $42
2025-07-22
maintain
Buy
Reason
Citi raised the firm's price target on Royalty Pharma to $42 from $40 and keeps a Buy rating on the shares as part of a Q2 earnings preview for the biotechnology group. The firm says Q2 is typically seasonally strong for the large biopharma names.
Morgan Stanley
Terence Flynn
Overweight
maintain
$51 -> $54
2025-07-10
Reason
Morgan Stanley
Terence Flynn
Price Target
$51 -> $54
2025-07-10
maintain
Overweight
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on Royalty Pharma to $54 from $51 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Morgan Stanley
Overweight
initiated
$51
2025-05-16
Reason
Morgan Stanley
Price Target
$51
2025-05-16
initiated
Overweight
Reason
Morgan Stanley resumed coverage of Royalty Pharma with an Overweight rating and $51 price target. The firm cites se the company's diversified portfolio and insulation from potential tariffs, coupled with a growth profile above the peer average, as positives.
Citigroup
Andrew Baum
Strong Buy
Maintains
$60 → $40
2024-10-25
Reason
Citigroup
Andrew Baum
Price Target
$60 → $40
2024-10-25
Maintains
Strong Buy
Reason
Goldman Sachs
Chris Shibutani
Strong Buy
Maintains
$50 → $51
2024-08-14
Reason
Goldman Sachs
Chris Shibutani
Price Target
$50 → $51
2024-08-14
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Royalty Pharma PLC (RPRX.O) is 7.99, compared to its 5-year average forward P/E of 10.56. For a more detailed relative valuation and DCF analysis to assess Royalty Pharma PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
10.56
Current PE
7.99
Overvalued PE
14.05
Undervalued PE
7.07
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
10.67
Current EV/EBITDA
8.83
Overvalued EV/EBITDA
12.88
Undervalued EV/EBITDA
8.45
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
6.12
Current PS
5.00
Overvalued PS
7.54
Undervalued PS
4.71
Financials
Annual
Quarterly
FY2025Q1
YoY :
+0.05%
568.25M
Total Revenue
FY2025Q1
YoY :
-824.08%
534.18M
Operating Profit
FY2025Q1
YoY :
-10243.53%
433.43M
Net Income after Tax
FY2025Q1
YoY :
+5400.00%
0.55
EPS - Diluted
FY2025Q1
YoY :
+2.85%
595.02M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-72.84%
12.36
FCF Margin - %
FY2025Q1
YoY :
-10270.67%
76.28
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 100.83% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
2.6M
Volume
3
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
5.2M
Volume
Months
6-9
6
2.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
RPRX News & Events
Events Timeline
2025-07-17 (ET)
2025-07-17
08:23:22
Royalty Pharma appoints Ho, Weatherman to board of directors

2025-06-24 (ET)
2025-06-24
07:15:30
Royalty Pharma announces $2B funding arrangement with Revolution Medicines

2025-06-24
07:13:36
Revolution Medicines enters $2B funding agreement with Royalty Pharma

Sign Up For More Events
Sign Up For More Events
News
8.0
07-18Yahoo FinanceRoyalty Pharma Declares Third Quarter 2025 Dividend
5.0
07-17NewsfilterRoyalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors
5.0
07-17Yahoo FinanceRoyalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
Sign Up For More News
People Also Watch

FIX
Comfort Systems USA Inc
688.740
USD
+22.37%

JBL
Jabil Inc
222.550
USD
+1.90%

ARE
Alexandria Real Estate Equities Inc
82.190
USD
+0.17%

MAA
Mid-America Apartment Communities Inc
151.650
USD
-0.02%

BBY
Best Buy Co Inc
67.440
USD
+0.22%

NMR
Nomura Holdings Inc
6.790
USD
+0.59%

KSPI
Kaspi.kz AO
85.000
USD
-0.79%

NI
NiSource Inc
42.180
USD
+0.67%

DOCU
DocuSign Inc
79.870
USD
-0.57%

FDS
Factset Research Systems Inc
419.540
USD
-0.46%
FAQ

What is Royalty Pharma PLC (RPRX) stock price today?
The current price of RPRX is 36.67 USD — it has increased 0.22 % in the last trading day.

What is Royalty Pharma PLC (RPRX)'s business?

What is the price predicton of RPRX Stock?

What is Royalty Pharma PLC (RPRX)'s revenue for the last quarter?

What is Royalty Pharma PLC (RPRX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Royalty Pharma PLC (RPRX)'s fundamentals?

How many employees does Royalty Pharma PLC (RPRX). have?
